Dynamic Technology Lab Private Ltd Acquires Shares of 18,095 Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Dynamic Technology Lab Private Ltd purchased a new position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,095 shares of the company’s stock, valued at approximately $34,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRSN. Vanguard Group Inc. boosted its holdings in Mersana Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 6,274,370 shares of the company’s stock valued at $28,109,000 after acquiring an additional 36,782 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Mersana Therapeutics by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,448,219 shares of the company’s stock worth $2,911,000 after buying an additional 20,400 shares in the last quarter. HealthInvest Partners AB increased its holdings in Mersana Therapeutics by 191.3% in the 3rd quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock worth $1,018,000 after buying an additional 353,721 shares in the last quarter. ClariVest Asset Management LLC increased its holdings in Mersana Therapeutics by 6.1% in the 2nd quarter. ClariVest Asset Management LLC now owns 500,498 shares of the company’s stock worth $1,006,000 after buying an additional 28,650 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Mersana Therapeutics by 19.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 452,829 shares of the company’s stock valued at $910,000 after purchasing an additional 74,092 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Martin H. Jr. Huber sold 50,423 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $1.76, for a total transaction of $88,744.48. Following the transaction, the chief executive officer now owns 116,327 shares in the company, valued at $204,735.52. This trade represents a 30.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 70,849 shares of company stock worth $129,184. 11.80% of the stock is currently owned by insiders.

Mersana Therapeutics Stock Up 3.0 %

Mersana Therapeutics stock opened at $2.37 on Wednesday. The business has a 50 day simple moving average of $2.08 and a 200-day simple moving average of $1.98. Mersana Therapeutics, Inc. has a 12 month low of $1.22 and a 12 month high of $6.28. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The stock has a market capitalization of $292.77 million, a PE ratio of -3.89 and a beta of 1.40.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate of $7.53 million. During the same quarter in the prior year, the business earned ($0.35) EPS. Mersana Therapeutics’s revenue was up 63.6% on a year-over-year basis. On average, analysts anticipate that Mersana Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRSN has been the subject of a number of recent research reports. Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Robert W. Baird decreased their price target on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.